Please login to the form below

Not currently logged in
Email:
Password:

Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s

Patients from a small phase 2a study saw their ADAS-Cog11 scores improve by 4.4 points

Biotech company Annovis Bio has revealed positive results for its lead investigational therapeutic ANVS401 in Alzheimer’s disease (AD) and Parkinson’s disease (PD).

The results come from a small phase 2a study evaluating ANVS401 in 14 AD patients and 14 PD patients.

The results show that patients treated with ANVS401 for 25 days achieved statistically significant cognitive improvement, measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11).

Specifically, patients in the ANVS401-treated group saw their ADAS-Cog11 scores improve by 4.4 points from baseline until 25 days – an improvement of 30%.

The ANVS401 treatment group also showed an improvement of 3.3 points (22%) compared to placebo at 25 days.

Biogen’s aducanumab, in comparison, showed a 1.4 point improvement in ADAS-Cog13 over 18 months, while a phase 2 study of Cassava’s simufilam demonstrated a 1.6 point improvement on ADAS-Cog11 after six months.

“The results from the first cohort of 14 AD and 14 PD patients show that the drug is effective in both diseases. Seeing efficacy in both patient populations supports our hypothesis that the impairment of axonal transport, the information highway of the nerve cell, affects nerve cells in the same way in both diseases,” said Maria Maccecchini, chief executive officer of Annovis Bio.

“The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins, which impair axonal transport, increase inflammation and eventually lead to nerve cell death and permanent loss of cognition and function,” she added.

ANVS401 is designed to inhibit the translation of multiple neurotoxic proteins – high levels of neurotoxic proteins result in impaired axonal transport, which plays a key role in the communication between and within nerve cells.

Through this inhibition, ANVS401 can improve axonal transport, reduce inflammation, protects nerve cell death and improve cognition and function, Annovis said in a statement.

Annovis is continuing to analyse the cerebral spine fluid and plasma samples of the first 28 patients from the phase 2a study, with the aim of measuring the reversal of the toxic cascade.

Additional data is expected to be revealed in the next two months, the company added, with full study data anticipated in July or August 2021.

When the phase 2a study is completed, Annovis said it will request a meeting with the US Food and Drug Administration (FDA) to present the results, along with its chronic toxicology study in animals.

Article by
Lucy Parsons

24th May 2021

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
VISFO

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

How ‘Greenwashing’ accusations could delay the very changes its supporters demand
Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...